Telemedics are being used to treat a range of ailments in hospitals around the world, with many people living in rural areas.
Now, in an attempt to help reduce the impact of infectious disease on rural communities, researchers are building telemedics to treat infectious diseases.
As the first-ever trial to tackle the disease, it will test the effectiveness of a new kind of pill that uses a small amount of the drug itself, rather than a generic drug.
The researchers behind the project, which is based at the National Institute of Allergy and Infectious Diseases (NIAID), have been working on a vaccine called Zmucin.
Zmucil was developed by Dr Peter Rokos at NIAID and his team at Cambridge University, who are working on using it to treat bacterial infections.
They are working to develop the drug in collaboration with a pharmaceutical company called Genentech.
“It’s really exciting,” Dr Rokus told Buzzfeed News.
“We’ve had an idea for a vaccine for a long time, but we’ve been doing it for a very long time and now this is the first time that we have actually been able to deliver it to people.”
The drug works by stimulating the immune system to fight off an infection, but is designed to last for around a week.
It can be taken once a week, for a maximum of 24 hours, and can help treat people with pneumonia and other respiratory conditions.
In the trial, researchers will test whether Zmugin can reduce the spread of the coronavirus by 80 percent in the villages they are working in.
While this could have an impact on the wider population, Dr Rosks team says the vaccine can also be used in rural settings where infections are common.
“The goal is to be able to see if we can reduce infectious disease cases in rural communities,” he said.
“We think that the vaccine is very effective in the village environment and we are trying to apply that to other areas of the world where infectious disease is common.”
Zoella is the biggest killer of rural communities in the world.
It causes severe illness and can lead to death, and is also the main cause of deaths in the US.
The World Health Organization estimates there are more than 50 million cases of the disease in the country, which includes 1.4 million deaths.
There are also around 500,000 infections each year in the UK, which has around 5,000 deaths, and more than 400,000 cases in the Netherlands.
In the US, the death rate is double the UK and is expected to triple by 2030.
But there are signs that the country is moving in the right direction.
This month, the US Centers for Disease Control and Prevention announced a dramatic shift in its strategy, which will see more than 4 million more people treated for the disease by the end of 2020, compared with the same period last year.